sorafenib has been researched along with 3-methyladenine in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (3-methyladenine) | Trials (3-methyladenine) | Recent Studies (post-2010) (3-methyladenine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,255 | 1 | 904 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, S; Gao, D; Gao, M; Liu, S; Lv, J; Niu, Z; Wang, X; Wang, Z | 1 |
| Feng, G; Guo, R; Liu, J; Su, Z; Zhai, Y; Zhang, H; Zhao, F; Zhu, J | 1 |
2 other study(ies) available for sorafenib and 3-methyladenine
| Article | Year |
|---|---|
Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.
Topics: Adenine; Animals; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Leucine; Lipid Metabolism; Mice; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib | 2021 |